BD’s fiscal fourth-quarter revenue rose 5.6% on a currency-neutral basis to $5.27bn, and adjusted EPS climbed 27.3% to $4.15.

Licensing remains a strategic R&D avenue for major developers even as the M&A market begins to recover. In Vivo has identified five high-value, unpartnered assets that could be the focus of dealmaking ...

Cardinal Health raised its fiscal 2027 non-GAAP EPS guidance to $12.80–$13 after first-quarter non-GAAP EPS rose to $3.26, ...

Despite changes in three senior roles and a $20m delayed biosimilar shipment cutting Biocon's Q2 FY2027 net profits by 52%, management assured that underlying business momentum remains strong.

Europe’s research-based association warns that EU pharmaceutical sandbox plans could face fresh scrutiny from national ...

Asia-Pacific OTC sales grew just 1.5% in the 12 months to June, IQVIA told the APSMI Summit in Bali, with cough and cold the ...

Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their ...

Edwards Lifesciences reported 11.2% constant currency sales growth for the third quarter of 2026, bringing sales for the ...

An FDA official said the new council will coordinate supply chain work across product areas, but visibility will vary by ...

However, Bourla acknowledged Democrats likely will investigate aspects of the MFN deals when they take control in Congress.